Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61K39/12

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/210742PEPTIDE OF NOROVIRUS ORIGIN, POLYNUCLEOTIDE, ANTIBODY, COMPOSITION, METHOD FOR IDENTIFYING NEUTRALIZING EPITOPE FOR NOROVIRUS
WO 06.10.2022
Int.Class C12N 15/40
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
40Proteins from RNA viruses, e.g. flaviviruses
Appl.No PCT/JP2022/015581 Applicant DENKA COMPANY LIMITED Inventor FUKUSHIMA, Naoshi
The present invention provides a peptide that can be used to induce protective immunity to a norovirus that has a GII genotype. Provided is a peptide that includes a portion of the amino acid sequence of the P domain of the VP1 protein of a norovirus that has any genogroup II (GII) genotype (except genotype 4).
2.WO/2022/212361PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING SARS-COV-2 ANTIGENS AND METHODS OF USE
WO 06.10.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2022/022324 Applicant BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM Inventor YEE, Cassian
This disclosure provides for peptides useful for vaccination and other applications, engineered T cell Receptors (TCRs), cells comprising the peptides and TCRs, and methods of making and using the peptides and TCRs. The current disclosure relates to TCRs that specifically recognize SARS-Cov-2 HLA-A2 restricted peptide from membrane glycol-protein (MGP), MGP-65: FVLAAVYRI (SEQ ID NO:22).
3.WO/2022/212511CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, COMPOSITIONS INCLUDING THE CLADE C HIV-1 ENVELOPE (ENV) TRIMER IMMUNOGENS, AND USES THEREOF
WO 06.10.2022
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
Appl.No PCT/US2022/022557 Applicant NOVA SOUTHEASTERN UNIVERSITY Inventor CAYABYAB, Mark J.
The invention encompasses a non-naturally occurring clade C human immunodeficiency virus type-1 (HIV-1) 1086.C envelope (ENV) SOSIP trimer protein. This trimer protein contains broadly neutralizing epitopes and epitopes that induce anti-V1/V2 antibodies and thus is an immunogen for creation of HIV-1 vaccines. The invention also includes prophylactic or therapeutic vaccine compositions/kits and methods for using the trimer protein as a component of a vaccine against HIV-1 infection.
4.WO/2022/211482VIRUS VACCINE BASED ON VIRUS SURFACE ENGINEERING PROVIDING INCREASED IMMUNITY
WO 06.10.2022
Int.Class C07K 14/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Appl.No PCT/KR2022/004491 Applicant THE INDUSTRY & ACADEMIC COOPERATION IN CHUNGNAM NATIONAL UNIVERSITY (IAC) Inventor SHIN, Hyun-Jin
The present invention relates to a virus vaccine based on virus surface engineering, wherein the virus vaccine provides increased immunity. A linker peptide according to one aspect of the present invention has the characteristic of being attachable to a virus, and thus can improve the immunogenicity of a vaccine by being used as a linker capable of effectively binding, to the virus surface, an immune-enhancing substance that activates the immune system. When the linker peptide is combined with virus surface engineering technology, the immune-enhancing substance can be attached to the virus surface, and thus the linker peptide may be effectively used as a vaccine platform providing increased immunity.
5.WO/2022/212289MUTANT HERPESVIRUS AND VACCINE COMPOSITIONS
WO 06.10.2022
Int.Class A61K 35/763
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
763Herpes virus
Appl.No PCT/US2022/022211 Applicant RATIONAL VACCINES, INC. Inventor FERNANDEZ, Agustin
Compositions and methods related to a mutant herpesvirus and a mutant ICPO protein. Vaccine compositions comprising the mutant herpesvirus and/or mutant ICPO protein. Methods of treatment using the mutant herpesvirus and/or mutant ICPO protein.
6.WO/2022/212499HIGHLY ATTENUATED REPLICATION-COMPETENT RECOMBINANT POXVIRUSES AS A VACCINE PLATFORM AND METHODS OF USE
WO 06.10.2022
Int.Class C12N 15/86
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
79Vectors or expression systems specially adapted for eukaryotic hosts
85for animal cells
86Viral vectors
Appl.No PCT/US2022/022541 Applicant ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY Inventor JACOBS, Bertram
Recombinant poxvirus expressing severe acute respiratory syndrome coronavirus 2 structural proteins and virus-like particles are described, along with methods of making and using the same.
7.WO/2022/204773CHIMERIC NUCLEOTIDE SEQUENCE, VECTOR FOR EXPRESSION IN MAMMALS, RNA VACCINE, CHIMERIC FUSION PROTEIN, USE IN THE PRODUCTION OF A VACCINE AGAINST CORONAVIRUS
WO 06.10.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/BR2022/050112 Applicant IMUNOTERA SOLUÇÕES TERAPÊUTICAS LTDA. Inventor ALVES, Rúbens Prince Dos Santos
The present invention pertains to the technical field of biotechnology. More specifically, a chimeric nucleotide sequence is described that corresponds to an encoded fusion protein comprising a polyepitope resulting from selecting and juxtaposing multiple epitopes from a coronavirus protein to induce an immune response in mammals. In one embodiment, said fusion protein comprises: a) a first peptide consisting of epitopes found in the amino acid sequence of replicase polyprotein 1ab (PR1ab); b) a first spacer; c) a modified form of herpes simplex virus type 1 (HSV-1) glycoprotein D (gD). In one embodiment, the replicase polyprotein is defined by SEQ ID NO: 96 flanked by a gD fragment comprising the amino acid sequence defined by SEQ ID NO: 98 in the N-terminal portion and another gD fragment comprising the amino acid sequence defined by SEQ ID NO: 100 in the C-terminal region. Use of the fusion protein has surprising results in inducing cellular and humoral immune responses against coronavirus, SARS-CoV-2, and related viruses.
8.WO/2022/207860COMBINATION THERAPY FOR COVID-19 VACCINATION
WO 06.10.2022
Int.Class A61K 31/085
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
075Ethers or acetals
085having an ether linkage to aromatic ring nuclear carbon
Appl.No PCT/EP2022/058688 Applicant DOMPE' FARMACEUTICI SPA Inventor ALLEGRETTI, Marcello
The present invention relates to the combination of a Selective Estrogen Receptor Modulator (SERM) and a COVID-19 vaccine.
9.WO/2022/212659MULTI-GENIC MRNA VACCINE COMPOSITIONS AND METHODS OF USE
WO 06.10.2022
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Appl.No PCT/US2022/022764 Applicant THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA Inventor EBERWINE, James
The present invention relates to multi-genic mRNA immunogenic compositions and methods for inducing an immune response against one or more pathogenic microorganism in a subject. In some embodiments, the present invention provides a composition comprising at least one mRNA molecule encoding a plurality of pathogen antigens.
10.WO/2022/206222NOVEL CORONAVIRUS S-RBD TRIMERIC PROTEIN VACCINE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF
WO 06.10.2022
Int.Class C07K 14/165
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
Appl.No PCT/CN2022/077527 Applicant NATIONAL VACCINE AND SERUM INSTITUTE(NVSI) Inventor LI, Qiming
Disclosed is a novel coronavirus S-RBD trimeric protein. The trimeric protein is composed of amino acid fragments of positions 319-537 in an RBD region of a novel coronavirus S protein in a trimeric form. A vaccine prepared by the present invention uses the S-RBD trimeric protein as an antigen; once an adjuvant is added, the body can be immunized and high-titer protective neutralizing antibodies against the novel coronavirus can be produced. The vaccine can be used for the treatment and/or prevention of novel coronavirus (SARS-CoV-2) infections and/or novel coronavirus diseases.